Quarterly ResultAug 5, 2026, 04:34 PM
AbCellera Q2 Net Loss $(55.4)M; Revenue $(4.1)M; New Jazz, Vertex Deals
AI Summary
AbCellera Biologics reported a net loss of $(55.4) million for Q2 2026, widening from $(34.7) million in Q2 2025, while total revenue decreased significantly to $4.1 million from $17.1 million year-over-year. For the first six months of 2026, the net loss was $(98.6) million on $12.4 million in revenue. The company also announced new collaboration agreements, including a $56.0 million upfront payment from Jazz Pharmaceuticals in June 2026 and a $28.0 million upfront payment from Vertex Pharmaceuticals in July 2026, for multispecific antibody development.
Key Highlights
- Q2 2026 net loss increased to $(55.4) million from $(34.7) million in Q2 2025.
- Q2 2026 total revenue decreased to $4.1 million from $17.1 million in Q2 2025.
- H1 2026 net loss was $(98.6) million, up from $(80.3) million in H1 2025.
- H1 2026 total revenue decreased to $12.4 million from $21.3 million in H1 2025.
- Cash and cash equivalents were $120.1 million as of June 30, 2026.
- Received $56.0 million upfront from Jazz Pharmaceuticals for a new collaboration.
- Received $28.0 million upfront from Vertex Pharmaceuticals for a new collaboration.
- Company highlighted risks including inability to achieve profitability and fluctuating results.
Price Impact
More from ABCL